Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
Zarir F. Udwadia,
Hanmant Barkate,
Saiprasad Patil,
Shabbir Rangwala,
Wen Wu,
Cynthia F. Caracta,
Monika Tandon
Affiliations
Zarir F. Udwadia
Breach Candy Hospital, Mumbai, India
Hanmant Barkate
Glenmark Pharmaceuticals Limited, Mumbai, India
Saiprasad Patil
Glenmark Pharmaceuticals Limited, Mumbai, India
Shabbir Rangwala
Glenmark Pharmaceuticals Limited, Mumbai, India
Wen Wu
Glenmark Pharmaceuticals Ltd, Watford, UK
Cynthia F. Caracta
Glenmark Pharmaceuticals, Inc., Mahwah, NJ, USA
Monika Tandon
Corresponding author.; Glenmark Pharmaceuticals Limited, Mumbai, India
